Targeted Melanoma Therapy Offers Better Outcomes and Fewer Side Effects

It’s a very exciting time for melanoma research. And more options than ever are becoming available to metastatic melanoma patients. Dr. Lynn Mara Schuchter, of the Abramson Cancer Center at the University of Pennsylvania and a leader in much of the ongoing research, talks about the significant progress in identifying new melanoma gene mutations and the targeted therapies that are becoming available with much lower toxicity than older treatments. Patient advocate and blogger, Dr. Brian Koffman interviews Dr. Schuchter at the 2013 American Society of Clinical Oncology Meeting. Watch now.

Get email alerts | http://www.patientpower.info/

Subscribe on YouTube | http://bit.ly/patientpowerYT
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower